Table 2.
Analysis of the treatment ranking
| Treatment | P score (fixed) | P score (random) |
|---|---|---|
| Progression free survival | ||
| Avelumab plus axitinib | 0.8255 | 0.8255 |
| Pembrolizumab plus axitinib | 0.8002 | 0.8002 |
| Atezolizumab plus bevacizumab | 0.5679 | 0.5679 |
| Nivolumab plus ipilimumab | 0.5316 | 0.5316 |
| IMA901 plus sunitinib | 0.3122 | 0.3122 |
| Sunitinb | 0.2377 | 0.2377 |
| Pazopanib | 0.2249 | 0.2249 |
| Overall survival | ||
| Pembrolizumab plus axitinib | 0.8052 | 0.8052 |
| Nivolumab plus ipilimumab | 0.7625 | 0.7625 |
| Avelumab plus axitinib | 0.6141 | 0.6141 |
| Pazopanib | 0.433 | 0.433 |
| Atezolizumab plus bevacizumab | 0.4094 | 0.4094 |
| Sunitinb | 0.2721 | 0.2721 |
| IMA901 plus sunitinib | 0.2038 | 0.2038 |
| Adverse events | ||
| Nivolumab plus ipilimumab | 0.9999 | 0.9999 |
| Sunitinb | 0.5985 | 0.5985 |
| Avelumab plus axitinib | 0.5944 | 0.5944 |
| Pazopanib | 0.4817 | 0.4817 |
| Pembrolizumab plus axitinib | 0.2517 | 0.2517 |
| IMA901 plus sunitinib | 0.0737 | 0.0737 |